#WHO grants approval for safe effective meningitis A vaccine for infants The World health organization (WHO) has opened the door to routine immunization of infants in Sub-saharan africa by approving for use an innovative and affordable vaccine that has all but rid the meningitis belt of a major cause
The announcement was made today by the Meningitis Vaccine Project (MVP)--a partnership between the global health nonprofit PATH and WHO--and Serum institute of india Ltd (SIIL),
which manufactures the Menafrivac vaccine.""Initial mass vaccination campaigns with Menafrivac have been highly effective in reducing the number of meningitis A cases,
5 g dose of the meningitis A vaccine meets international standards of quality, safety, and efficacy and can
The only existing vaccine was insufficient to break the cycle. Protection at an affordable price In 2004, MVP partnered with SIIL to develop an affordable, tailor-made vaccine for use against meningitis A in Sub-saharan africa.
Menafrivac was developed in record time at less than 1 tenth the cost of a typical new vaccine. Since campaigns started in 2010,
Menafrivac has been administered to over 215 million people in 15 countries of the African meningitis belt:
"Developing the Menafrivac vaccine fit exactly Serum's ingrained philosophy of bringing down prices of vaccines
"One year after large-scale vaccine introduction in late 2010, for example, experience from Burkina faso provided early evidence that mass vaccination was associated with a significantly reduced risk of meningitis in the targeted population,
Support from Gavi, the Vaccine Alliance; the United nations children's fund (UNICEF; PATH; WHO; and national governments has been crucial for mass vaccination campaigns that are due to continue until 2016 to cover at-risk populations in all 26 countries where disease burden from meningitis A is greatest.
and optimal dosage and immunization schedule for administering Menafrivac to infants and toddlers alongside other routine childhood vaccines in African meningitis belt countries.
Results from two infant clinical studies in Ghana and Mali and vaccine introduction impact data were presented to THE WHO Strategic Advisory Group of Experts on Immunization (SAGE) in October 2014
Specifically, THE WHO prequalification that was announced today allows United nations procurement agencies to purchase the vaccine for use in routine immunization programs in meningitis-belt countries
Menafrivac was the first vaccine developed outside"traditional pharma, "and the only vaccine developed specifically for people in Africa."
"With Menafrivac, we created a revolutionary new model for vaccine development and now we stand on the brink of protecting an entire generation,
and those to come, from a devastating disease, "said Dr. Kathy Neuzil, director of Vaccine Access and Delivery at PATH."
"Our efforts began with a request by African leaders to address a major health challenge affecting hundreds of millions of people,
effective vaccine could be developed and deployed across multiple countries at a price that was sustainable.""
""The benefits of childhood immunization last a lifetime and the Menafrivac vaccine is one of the greatest success stories that shows
"Prequalification of the Menafrivac vaccine for infants clears the way for the routine immunization of every child before his
""We are more than halfway through with introducing the vaccine in meningitis-belt countries, and the first introductions have been a stunning success,
"said Dr. Jeanmarie Okwo-Bele, director of THE WHO Department of Immunization, Vaccines and Biologicals.""But we cannot yet declare a win on meningitis epidemics in Sub-saharan africa.
and introduce the vaccine in the Expanded Programme on Immunization. Then and only then will we win the battle against meningitis. a
#New approach may lead to inhalable vaccines for influenza pneumonia The work led by Cathy Fromen
The findings published in the Proceedings of the National Academy of Sciences also have broad public health implications for improving the accessibility of vaccines.
An inhalable vaccine may eliminate the need for refrigeration which can not only improve shelf life but also enable distribution of vaccines to low-resource areas including many developing countries where there is significant need for better access to vaccines s
#Study pinpoints autism-linked protein for sculpting brain connections A new study by Duke researchers provides a close up of synapse refinement
But what we found was that in most cases including the reaction to a standard influenza vaccine
and medical director of the Stanford-Lucile Packard Children's Hospital Vaccine Program. While many previous studies have suggested a powerful genetic component in vaccine responsiveness Davis noted that those studies typically were performed in very young children who had undergone not yet the decades of environmental exposure that appears to reshape the immune system over time.
In a striking example of the immune system's plasticity the Stanford scientists found that the presence
Cancer researchers have been interested in these proteins as markers for cancer and as potential targets for therapeutic cancer vaccines."
"We have designed a vaccine-style treatment or'immunotherapy'specifically for individuals carrying high-risk rheumatoid arthritis genes and specific rheumatoid arthritis antibodies, called anti-CCP."
clinically-practical vaccine technology that could deliver similar outcomes for patients. Professor Thomas is working on a delivery technology with Dendright Pty Ltd (a Uniquest start-up company) in collaboration Janssen Biotech Inc,
Their findings on viral epitopes may also have important implications for vaccine design. Elledge says the approach his team has developed is limited not to antiviral antibodies.
#Protein discovery fuels redesign of mosquito-based malaria vaccine A promising type of vaccine designed to eradicate malaria by blocking parasite transmission could be a step closer,
Malaria transmission-blocking vaccines are designed to prevent the spread of malaria by interrupting parasite transmission.
The Anapn1 protein is a leading candidate for a mosquito-based malaria transmission-blocking vaccine that is being developed by Dr Dinglasan."
"This type of vaccine won't boost people's immunity to malaria, but instead it will provide a delayed benefit to the individual by protecting the entire community from parasite transmission,
Dr Dinglasan said as a vaccine antigen, Anapn1 prompts people to make antibodies; however only some of these antibodies block parasite transmission,
To further improve vaccine immunogenicity at the preclinical stage, we need to immuno-focus the antibody response to only the critical,
when infected by the virus. There is a safe and effective vaccine available, the researchers say,
if the vaccine were used in Nepal during monsoon season, which runs from July to September.
that the Nepalese Ministry of Health should initiate a request for the vaccine and build a stockpile;
and develop targeted deployment strategies for the use of the vaccine, based on identification of high-risk populations and the available organizational capacity for safe implementation and monitoring of outcomes."
"These findings now explain why it is difficult to develop vaccines against tuberculosis, "said Dr. Das."
"The immune cells activated by the vaccine agent may not be able to reach the hypoxic site of bone marrow to target these"wolfs-in-stem-cell-clothing."
""The hope for a definitive cure and an effective vaccine has been frustrated by HIV's endless propensity to subvert the host's defences
#Scientists successfully test immunogen a component for potential HIV vaccine Team of researchers from The Scripps Research Institute, INTERNATIONAL AIDS Vaccine Initiative and The Rockefeller University have shown successfully that an experimental vaccine candidate
In fact, scientists believe that findings of the study could provide key information for the development of an effective AIDS vaccine.
may become one of the parts of first successful HIV vaccine. Image credit: scripps. eduefforts to create effective vaccine against HIV so far have been virtually fruitless.
However, scientists already describe results of this latest research as spectacular. The long-term goal of the research is to develop a vaccine that prompts the body to produce antibodies that bind to HIV
and prevent infection and current experiments with mice models showed promising results. Many vaccines for other diseases use a dead
or inactive version of the disease-causing microbe itself to trigger antibody production. However, this simple approach does not work with HIV immunizations with ativehiv proteins are ineffective in triggering an effective immune response
This makes HIV vaccine a particularly challenging task for scientists, which explains why science still has produced not an effective one.
This challenge did not make scientists believe that AIDS vaccine is impossible. Instead they figured out that it has to consist of a series of related,
Professor David Nemazee evaluated results like that he vaccine appears to work well in our mouse model to rimethe antibody response In another research scientists used the same immunogen in a slightly different mouse model,
which showed promising results As well as scientists have taken approach to collect a variety of different immunogens to develop a united HIV vaccine,
HIV vaccine would be a major breakthrough at fight against AIDS, as it still is arguably the biggest threat to human population.
vaccine could be one of the greatest scientific achievements of the century. Source: Scripp s
Currently, there are no vaccines or treatments specifically for Marburg infections. The findings were published online ahead of print today in the journal Plos Pathogens.
The high cost of creating independent vaccines or treatments for each of the different viruses in this family necessitates intelligent design of immunogens (antibody-inducing molecules).
#HIV vaccine: Pushing the Envelope A new study led by scientists at Harvard Medical school and Beth Israel Deaconess Medical center demonstrates that a heterologous prime-boost HIV-1 vaccine regimen protected 50 percent of vaccinated nonhuman primates against challenges with the simian immunodeficiency virus (SIV),
a virus similar to HIV that infects nonhuman primates. Published in the July 2 online edition of Science, these new findings provide a new strategy for the clinical development of this novel HIV-1 vaccine candidate. espite the urgent need for a safe and effective
global HIV-1 vaccine, only four vaccine concepts have been evaluated for protective efficacy in humans over the past 30 years,
said lead author Dan Barouch, HMS professor of medicine and director of the Center for Virology and Vaccine Research at Beth Israel Deaconess. e are encouraged very by the results of this latest preclinical HIV-1 vaccine study
and believe the findings may lead to a clear path forward for evaluating this HIV vaccine candidate in humans.
In this work, nonhuman primates were given first a dose of adenovirus serotype 26 vectored vaccine to rimethe immune system to mount an antibody response
and then received a oostwith a purified HIV envelope protein (the surface protein of HIV),
which enhances the immune system over time. Adenovirus 26 is responsible for the common cold and is engineered to serve as a carrier,
The study results showed that the prime-boost vaccine regimen provided complete protection in half of the vaccinated nonhuman primates against a series of six repeated challenges with SIV. ur previous studies
of viral vector-based HIV-1 vaccine candidates showed much lower levels of protection against SIV,
Based on these preclinical data, the HIV-1 version of this vaccine regimen is now being evaluated in an ongoing international clinical study sponsored by Crucell Holland BV
the definitive solution to this epidemic will likely be said a vaccine Barouch. hese new findings represent an important step forward. s
#Could dissolvable microneedles replace injected vaccines? The microneedle patch can dissolve in the skin, delivering the flu vaccine painlessly.
New vaccine patch protects against flu in humansflu vaccines delivered using microneedles that dissolve in the skin can protect people against infection even better than the standard needle-delivered vaccine,
according to new research published in Biomaterials. The authors of the study, from Osaka University in Japan, say their dissolvable patch the only vaccination system of its kind could make vaccination easier, safer and less painful.
The continued threat of pandemics such as H1n1 swine flu and emerging infectious diseases such as Ebola makes vaccine development and mass vaccination a priority for global healthcare.
Most vaccines are injected under the skin or into the muscle using needles. While this is an effective delivery method,
taking the vaccine with them. The researchers compared the new system to traditional needle delivery by vaccinating two groups of people against three strains of influenza:
A/H1n1, A/H3n2 and B. None of the subjects had a bad reaction to the vaccine,
people given the vaccine using the microneedles had an immune reaction that was equal to or stronger than those given the vaccine by injection. e were excited to see that our new microneedle patch is
just as effective as the needle-delivered flu vaccines, and in some cases even more effective, said Professor Nakagawa.
Previous research has evaluated the use of microneedles made of silicon or metal, but they were shown not to be safe.
we think it could bring about a major change in the way we administer vaccines globally, said Professor Nakagawa.
and an effective vaccine has been frustrated by HIV endless propensity to subvert the host defences and persist in small populations of long-lasting reservoirs despite antiretroviral therapy,
and deliver drugs and vaccines, a olar spongethat can capture and release carbon dioxide emissions andplastic material that gets better with age.
#World's first malaria vaccine gets green light from European regulatory agency The world's first malaria vaccine has cleared its last major hurdle on its way to being approved for real-world use.
The European Medicines Agency (EMA) the regulatory group in the European union which roughly parallels the FDA gave a positive opinion of the vaccine,
The vaccine RTS S, also called Mosquirix, is the product of British pharmaceutical company Glaxosmithkline and is funded partly by the Bill and Melinda Gates Foundation.
It's not the only vaccine developed to fight malaria; an experimental malaria vaccine called Pfspz was found to be much more effective at preventing malaria infection.
Yet Mosquirix is the first to make it this far along in the approval process. Mosquirix helps to prevent infection from the Plasmodium falciparum, one of the deadlier malaria parasites.
The vaccine prompts the body to produce a higher amount of antibodies to stop the parasite from infecting the liver.
Early results of a clinical trial of Mosquirix showed that three doses of the vaccine could cut the risk of infection in half for children between between five and 17 months old.
and somewhat ineffective vaccine may outweigh the benefits. Still, Africa is need in desperate for a malaria vaccine,
even if it's only partially effective. Malaria infection spread through the blood by mosquito bites kills upwards of 500
"This vaccine could mean children will have only two bouts of malaria a year instead of five,"Dr. Martin De Smet,
#Ebola vaccine is 100 percent effective in Guinea trial, WHO reports A vaccine is"highly effective"against Ebola, according to the World health organization.
Early results from a trial in Guinea show that the drug protected 100 percent of the people who received it against Ebola.
the vaccine could help end the outbreak in West Africa.""The initial results are exciting and very promising,
and the hunt for a vaccine continues. Now, it seems that scientists have a real contender on their hands.
4, 000 people with close ties to Ebola patients either received the vaccine immediately or three weeks after the identification of an Ebola patient in their social circle.
There were 16 cases of Ebola in the group that were given the vaccine three weeks later, however."
Starting July 26th, all of the study's participants were given the vaccine immediately, instead of putting half in a delayed group.
These results don't mean that the world now has an Ebola vaccine. The vaccine needs to undergo further safety and efficacy testing.
The vaccine is also being tested on frontline health workers, Bertrand Draguez, medical director at Doctors Without Borders, said in a statement."
"These people have worked tirelessly and put their lives at risk every day to take care of sick people,
"If the vaccine is effective, then we are already protecting them from the virus. i
#HPV Vaccine Is Effective Against Multiple Cancer-Causing Strains The human papillomavirus vaccine, Cervarix, not only has the potential to prevent cervical cancer,
They found that the vaccine was extremely effective in young women who had never been infected with HPV.
The vaccine was distinctly more effective among ages 15-17 than ages18-25, underscoring the value of vaccinating young adolescents,
The overall trial constituted the basis for approval of the Cervarix vaccine in Europe and the United states. While the trial did not investigate the vaccine's efficacy in males, sexually transmitted HPV causes anogenital and head and neck cancers in both males and females.
HPV-related head and neck cancers now number around 8, 400 in the United states, annually."
The findings are detailed in the journal Clinical and Vaccine Immunology y
#Mastercard seeks to move digital money fast NEW YORK Mastercard wants to speed up digital payments. The financial services giant has launched just Mastercard Send,
< Back - Next >
Overtext Web Module V3.0 Alpha
Copyright Semantic-Knowledge, 1994-2011